We would like to emphasize some other important aspects of using AChE-selective inhibitors to treat MG. Pharmacokinetics of specific AChE inhibitors should be obviously distinct from that of non-specific inhibitors because BChE is highly abundant in serum and other tissues22. The gene discussed is ACHE; the disease is myasthenia gravis.